login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News
USA
-
Nasdaq
- NASDAQ:ARQT -
US03969K1088
-
Common Stock
30.73
USD
-0.03 (-0.1%)
Last: 11/25/2025, 8:25:31 PM
30.67
USD
-0.06 (-0.2%)
After Hours:
11/25/2025, 8:25:31 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ARQT Latest News, Press Relases and Analysis
All
Press Releases
16 days ago - By: Chartmill
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum
5 days ago - By: The Motley Fool
Why Shares in Arcutis Biotherapeutics Surged Again This Week
5 days ago - By: Zacks Investment Research
- Mentions:
ADMA
EDIT
COGT
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
6 days ago - By: Zacks Investment Research
- Mentions:
GILD
MRK
ADMA
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
6 days ago - By: Zacks Investment Research
- Mentions:
PHAR
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
6 days ago - By: Benzinga
- Mentions:
ARWR
HSIC
HUM
LLY
...
10 Health Care Stocks With Whale Alerts In Today's Session
7 days ago - By: Zacks Investment Research
- Mentions:
NVO
VNDA
ADMA
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
7 days ago - By: Zacks Investment Research
- Mentions:
NVO
ADMA
VTYX
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
8 days ago - By: Zacks Investment Research
- Mentions:
GSK
ADMA
ALEC
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
9 days ago - By: Zacks Investment Research
- Mentions:
BTSG
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
9 days ago - By: Zacks Investment Research
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
9 days ago - By: Arcutis Biotherapeutics, Inc.
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
9 days ago - By: Arcutis Biotherapeutics, Inc.
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
12 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ADMA
KOD
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
12 days ago - By: Benzinga
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest
13 days ago - By: Zacks Investment Research
- Mentions:
NVS
ANIP
ADMA
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
13 days ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
15 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ADMA
EDIT
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
18 days ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 days ago - By: Zacks Investment Research
- Mentions:
SNY
NVAX
ANIP
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
19 days ago - By: Zacks Investment Research
- Mentions:
RDY
ANIP
ESPR
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
19 days ago - By: Zacks Investment Research
- Mentions:
PBYI
ANIP
SNDX
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
20 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ACAD
SNDX
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
20 days ago - By: Zacks Investment Research
- Mentions:
TEVA
ANIP
SNDX
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
21 days ago - By: Zacks Investment Research
- Mentions:
ANIP
NTLA
MIRM
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
21 days ago - By: Zacks Investment Research
- Mentions:
CORT
ANIP
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
21 days ago - By: Zacks Investment Research
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade
22 days ago - By: Zacks Investment Research
- Mentions:
TGTX
ANIP
NTLA
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
22 days ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
22 days ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
26 days ago - By: Zacks Investment Research
- Mentions:
EXAS
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
a month ago - By: Zacks Investment Research
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock
a month ago - By: Zacks Investment Research
- Mentions:
GRFS
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
a month ago - By: Arcutis Biotherapeutics, Inc.
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
a month ago - By: Arcutis Biotherapeutics, Inc.
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
a month ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
a month ago - By: Arcutis Biotherapeutics, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
a month ago - By: The Motley Fool
Arcutis Q3 2025 Earnings Call Transcript
Please enable JavaScript to continue using this application.